Operating margin
24.6% Fiscal year 2025
No rank: too few peers or not computed yet.
Operating income divided by revenue: what the core business earns before interest and taxes.
About the company
AbbVie is a US pharmaceutical company that was spun off from Abbott in 2013. Its focus areas are immunology (Skyrizi, Rinvoq, formerly Humira), cancer drugs, neuroscience and aesthetic medicine with Botox. Its medicines are sold worldwide. As of Oct 11, 2026
Fact sheet (from the annual report) Pharmaceutical manufacturers · North Chicago, USA
According to the company, it is a global research-based biopharmaceutical company with a single business segment. Its therapeutic areas are immunology, neuroscience, oncology and aesthetics. Immunology includes Skyrizi, approved among other uses for moderate to severe plaque psoriasis, and Rinvoq, approved among other uses for rheumatoid arthritis. In neuroscience the company markets Vraylar for schizophrenia and Botox Therapeutic, for example for chronic migraine. Important customers also include managed care providers such as pharmacy benefit managers, as well as hospitals and government bodies such as the Medicaid programs; external partners handle parts of manufacturing.
Automatically summarized from SEC annual report (10-K, filed Feb 20, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026
Price performance at a glance
Last 30 trading days
- Today +0.4%
- 7 days +1.4%
- 30 days +8.5%
- 1 year +25.8%
Day range (last trading day)
−0.5%Price at 35% of the range+1.0%
52-week range
−33.5%Price at 95% of the range+1.6%
- Distance from the all-time high
- −1.6%
Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Fundamentals · Analysis method
Growth, margin and debt compared with the sector – in detail in the fundamental analysis further down. The chart shows the candles without a buy zone.
Growth: yellowMargin: yellowDebt: gray
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and marginAbbVie · Sector Health Care · amounts in USD
Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 20, 2026.
Quality checks
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
Fiscal year to Dec 31, 2025
Quality
Profitability, consistency, balance sheet · 2 without data
4 of 6 criteria met
Growth
Revenue and earnings per share
4 of 7 criteria met
Dividend
Level, consistency, coverage · 1 without data
5 of 6 criteria met
Financial strength
Piotroski, debt, liquidity
2 of 6 criteria met
Quality 4 of 6 met · 2 without data
- no data: Gross margin above 40% not stated in the SEC filings
- met: Operating margin above 15% 24.6%
- not met: Net margin above 10% 6.9%
- no data: Return on equity above 15% negative equity
- met: Free cash flow margin above 10% 29.1%
- met: Profit in each of the last 5 fiscal years 5 of 5
- met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
- not met: Equity ratio above 30% −2.4%
Net margin
6.9% Fiscal year 2025
No rank: too few peers or not computed yet.
Profit after all costs, interest and taxes divided by revenue.
Return on assets
3.2% Fiscal year 2025 (total assets at year end)
No rank: too few peers or not computed yet.
Net income divided by total assets at fiscal year end.
Equity ratio
−2.4% Fiscal year 2025
No rank: too few peers or not computed yet.
Equity as a share of total assets. Usually low for banks.
Free cash flow margin
29.1% Fiscal year 2025
No rank: too few peers or not computed yet.
Free cash flow divided by revenue.
Free cash flow
17.8B USD Fiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
Growth 4 of 7 met
- not met: Over 3 years, revenue grew by more than 5% per year +1.8%
- met: Over 5 years, revenue grew by more than 5% per year +6.0%
- met: Over 10 years, revenue grew by more than 5% per year +10.3%
- not met: Over 3 years, EPS grew by more than 5% per year −29.1%
- not met: Over 5 years, EPS grew by more than 5% per year −2.8%
- met: Revenue rose in at least 4 of the last 5 fiscal years 4 of 5
- met: Revenue rose in the last fiscal year +8.6%
Revenue growth 3 years
+1.8% per year
No rank: too few peers or not computed yet.
Average growth per year over 3 fiscal years.
Revenue growth 5 years
+6.0% per year
No rank: too few peers or not computed yet.
Average growth per year over 5 fiscal years.
Revenue growth 10 years
+10.3% per year
No rank: too few peers or not computed yet.
Average growth per year over 10 fiscal years.
EPS growth 3 years
−29.1% per year
No rank: too few peers or not computed yet.
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 5 years
−2.8% per year
No rank: too few peers or not computed yet.
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 10 years
−2.8% per year
No rank: too few peers or not computed yet.
Growth of earnings per share per year, adjusted for stock splits.
Dividend 5 of 6 met · 1 without data
- met: Pays a dividend 6.65 USD
- not met: Payout ratio at most 60% of earnings 282%
- met: Dividend paid in each of the last 5 fiscal years 5 of 5
- met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
- met: Dividend per share higher than 5 years ago +6.6%
- met: Free cash flow per share covers the dividend 1.5x
- no data: Dividends paid over the last 5 years covered by free cash flow dividends paid or free cash flow reported for fewer than 3 years
Payout ratio
282% Fiscal year 2025
Dividend per share divided by earnings per share.
Dividend growth 5 years
+6.6% per year
No rank: too few peers or not computed yet.
Growth of the dividend per share per year.
Free cash flow coverage
1.5x Fiscal year 2025
Free cash flow per share divided by dividend per share. From 1x the dividend is covered.
Financial strength 2 of 6 met
- met: Piotroski F-Score at least 7 of 9 7 of 8 · 1 without data
- not met: Long-term debt no higher than equity negative equity
- not met: Current assets cover current liabilities 0.67
- not met: Positive equity −3.3B USD
- not met: In 5 years, share count up by at most 5% +6.0%
- met: Free cash flow positive in the last fiscal year 17.8B USD
Piotroski F-Score
7 of 8 Fiscal year 2025
No rank: not all 9 criteria have data.
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
Debt / equity
negative equity at fiscal year end
No rank: too few peers or not computed yet.
Long-term financial debt divided by equity.
Liquidity (current ratio)
0.67 at fiscal year end
No rank: too few peers or not computed yet.
Current assets divided by current liabilities.
Change in share count
+6.0% in 5 years
No rank: too few peers or not computed yet.
Change in diluted share count. Negative = share buybacks, positive = new shares.
The 9 criteria of the Piotroski F-Score
- met: Profit in the last fiscal year (positive return on assets)
- met: Positive operating cash flow
- not met: Return on assets higher than the prior year
- met: Operating cash flow higher than net income
- met: Long-term debt relative to total assets fell
- met: Liquidity (current assets / current liabilities) rose
- met: No additional shares (diluted share count did not rise)
- no data: Gross margin higher than the prior year
- met: Revenue relative to total assets higher than the prior year
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock.
In short
- Light yellow: Revenue grew over 5 years (+6.0% per year), more slowly than the sector median.
- Light red: Net income (total) shrank over 5 years (−1.7% per year); per share −2.8% per year.
- Light yellow: Net margin 6.9%, below the sector median (12.9%).
- Light green: Profit in each of the last 10 fiscal years.
- Light red: Dividend higher than earnings.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 25.6B USD · Net income 6.0B USD · Net margin 23.2%
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 28.2B USD · Net income 5.3B USD · Net margin 18.8%
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 32.8B USD · Net income 5.7B USD · Net margin 17.4%
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 33.3B USD · Net income 7.9B USD · Net margin 23.7%
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 45.8B USD · Net income 4.6B USD · Net margin 10.1%
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 56.2B USD · Net income 11.5B USD · Net margin 20.5%
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 58.1B USD · Net income 11.8B USD · Net margin 20.4%
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 54.3B USD · Net income 4.9B USD · Net margin 9.0%
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 56.3B USD · Net income 4.3B USD · Net margin 7.6%
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 61.2B USD · Net income 4.2B USD · Net margin 6.9%
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Revenue 13.9B USD · Net income 1.8B USD · Net margin 12.8%
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 14.3B USD · Net income 822.0M USD · Net margin 5.7%
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 12.3B USD · Net income 1.4B USD · Net margin 11.1%
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 14.5B USD · Net income 1.4B USD · Net margin 9.5%
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 14.5B USD · Net income 1.6B USD · Net margin 10.8%
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 15.1B USD · Net income −22.0M USD · Net margin −0.1%
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 13.3B USD · Net income 1.3B USD · Net margin 9.6%
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 15.4B USD · Net income 938.0M USD · Net margin 6.1%
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 15.8B USD · Net income 186.0M USD · Net margin 1.2%
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 16.6B USD · Net income 1.8B USD · Net margin 10.9%
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 15.0B USD · Net income 695.0M USD · Net margin 4.6%
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 17.0B USD · Net income 3.6B USD · Net margin 21.3%
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Earnings per share 3.63 USD
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Earnings per share 3.30 USD
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Earnings per share 3.66 USD
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Earnings per share 5.28 USD
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Earnings per share 2.72 USD
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Earnings per share 6.45 USD
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Earnings per share 6.63 USD
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Earnings per share 2.72 USD
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Earnings per share 2.39 USD
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Earnings per share 2.36 USD
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Earnings per share 1.00 USD
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Earnings per share 0.46 USD
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Earnings per share 0.77 USD
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Earnings per share 0.77 USD
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Earnings per share 0.88 USD
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Earnings per share −0.02 USD
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Earnings per share 0.72 USD
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Earnings per share 0.52 USD
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Earnings per share 0.10 USD
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Earnings per share 1.02 USD
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Earnings per share 0.39 USD
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Earnings per share 2.03 USD
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Dividend per share 2.35 USD · Payout ratio 64.7%
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Dividend per share 2.63 USD · Payout ratio 79.7%
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Dividend per share 3.95 USD · Payout ratio 107.9%
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Dividend per share 4.39 USD · Payout ratio 83.1%
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Dividend per share 4.84 USD · Payout ratio 177.9%
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Dividend per share 5.31 USD · Payout ratio 82.3%
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Dividend per share 5.71 USD · Payout ratio 86.1%
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Dividend per share 5.99 USD · Payout ratio 220.2%
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Dividend per share 6.29 USD · Payout ratio 263.2%
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Dividend per share 6.65 USD · Payout ratio 281.8%
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Dividend per share 1.48 USD · Payout ratio 148.0%
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Dividend per share 1.55 USD · Payout ratio 337.0%
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Dividend per share 1.55 USD · Payout ratio 201.3%
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Dividend per share 1.55 USD · Payout ratio 201.3%
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Dividend per share 1.55 USD · Payout ratio 176.1%
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Dividend per share 1.64 USD · Payout ratio not available
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Dividend per share 1.64 USD · Payout ratio 227.8%
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Dividend per share 1.64 USD · Payout ratio 315.4%
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Dividend per share 1.64 USD · Payout ratio 1,640.0%
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Dividend per share 1.73 USD · Payout ratio 169.6%
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Dividend per share 1.73 USD · Payout ratio 443.6%
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Dividend per share 1.73 USD · Payout ratio 85.2%
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 61.2B USD · Net income 4.2B USD · Net margin 6.9%
Figures over time
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Money flow in fiscal year 2025
Of 100 USD of revenue, 24.6 USD operating income and 6.9 USD net income remained.
Money flow as a table
| Item | Amount | of revenue |
|---|---|---|
| Revenue | 61.2B USD | 100.0% |
| Operating income | 15.1B USD | 24.6% |
| Cost of revenue and operating expenses | 46.1B USD | 75.4% |
| Net income | 4.2B USD | 6.9% |
| Taxes, interest & other | 10.8B USD | 17.7% |
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
Margins
The operating margin stayed roughly the same in 5 years (24.6%).
Operating marginNet margin- Fiscal year 2016: Operating margin 36.6% · Net margin 23.2%
- Fiscal year 2017: Operating margin 34.0% · Net margin 18.8%
- Fiscal year 2018: Operating margin 19.5% · Net margin 17.4%
- Fiscal year 2019: Operating margin 39.0% · Net margin 23.7%
- Fiscal year 2020: Operating margin 24.8% · Net margin 10.1%
- Fiscal year 2021: Operating margin 31.9% · Net margin 20.5%
- Fiscal year 2022: Operating margin 31.2% · Net margin 20.4%
- Fiscal year 2023: Operating margin 23.5% · Net margin 9.0%
- Fiscal year 2024: Operating margin 16.2% · Net margin 7.6%
- Fiscal year 2025: Operating margin 24.6% · Net margin 6.9%
Returns
Return on equity rose in 3 years from 35.3% to 46.9%.
Return on equityReturn on assets Return on equity hidden where equity is below 5% of total assets.- Fiscal year 2016: Return on equity 128.4% · Return on assets 9.0%
- Fiscal year 2017: Return on equity 104.2% · Return on assets 7.5%
- Fiscal year 2018: Return on equity not available · Return on assets 9.6%
- Fiscal year 2019: Return on equity not available · Return on assets 8.8%
- Fiscal year 2020: Return on equity 35.3% · Return on assets 3.1%
- Fiscal year 2021: Return on equity 74.9% · Return on assets 7.9%
- Fiscal year 2022: Return on equity 68.6% · Return on assets 8.5%
- Fiscal year 2023: Return on equity 46.9% · Return on assets 3.6%
- Fiscal year 2024: Return on equity not available · Return on assets 3.2%
- Fiscal year 2025: Return on equity not available · Return on assets 3.2%
Equity and long-term debt
The equity ratio fell in 5 years from 8.7% to −2.4%.
EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.- Fiscal year 2016: Equity 4.6B USD · Long-term debt 36.4B USD
- Fiscal year 2017: Equity 5.1B USD · Long-term debt 31.0B USD
- Fiscal year 2018: Equity −8.4B USD · Long-term debt 35.0B USD
- Fiscal year 2019: Equity −8.2B USD · Long-term debt 63.0B USD
- Fiscal year 2020: Equity 13.1B USD · Long-term debt 77.6B USD
- Fiscal year 2021: Equity 15.4B USD · Long-term debt 64.2B USD
- Fiscal year 2022: Equity 17.3B USD · Long-term debt 59.1B USD
- Fiscal year 2023: Equity 10.4B USD · Long-term debt 52.2B USD
- Fiscal year 2024: Equity 3.3B USD · Long-term debt 60.3B USD
- Fiscal year 2025: Equity −3.3B USD · Long-term debt 58.9B USD
Liquidity (current ratio)
The current ratio fell in 5 years from 0.84 to 0.67.
Current ratio- Fiscal year 2016: Current ratio 1.65
- Fiscal year 2017: Current ratio 1.28
- Fiscal year 2018: Current ratio 0.98
- Fiscal year 2019: Current ratio 3.18
- Fiscal year 2020: Current ratio 0.84
- Fiscal year 2021: Current ratio 0.79
- Fiscal year 2022: Current ratio 0.96
- Fiscal year 2023: Current ratio 0.87
- Fiscal year 2024: Current ratio 0.66
- Fiscal year 2025: Current ratio 0.67
Cash flow
Free cash flow rose in 5 years from 16.8B USD to 17.8B USD.
Operating cash flowCapital expenditureFree cash flow in USD- Fiscal year 2016: Operating cash flow 7.0B USD · Capital expenditure 479.0M USD · Free cash flow 6.6B USD
- Fiscal year 2017: Operating cash flow 10.0B USD · Capital expenditure 529.0M USD · Free cash flow 9.4B USD
- Fiscal year 2018: Operating cash flow 13.4B USD · Capital expenditure 638.0M USD · Free cash flow 12.8B USD
- Fiscal year 2019: Operating cash flow 13.3B USD · Capital expenditure 552.0M USD · Free cash flow 12.8B USD
- Fiscal year 2020: Operating cash flow 17.6B USD · Capital expenditure 798.0M USD · Free cash flow 16.8B USD
- Fiscal year 2021: Operating cash flow 22.8B USD · Capital expenditure 787.0M USD · Free cash flow 22.0B USD
- Fiscal year 2022: Operating cash flow 24.9B USD · Capital expenditure 695.0M USD · Free cash flow 24.2B USD
- Fiscal year 2023: Operating cash flow 22.8B USD · Capital expenditure 777.0M USD · Free cash flow 22.1B USD
- Fiscal year 2024: Operating cash flow 18.8B USD · Capital expenditure 974.0M USD · Free cash flow 17.8B USD
- Fiscal year 2025: Operating cash flow 19.0B USD · Capital expenditure 1.2B USD · Free cash flow 17.8B USD
Share count
The share count rose in 5 years by 6.0% – more new shares were issued than repurchased (dilution).
Diluted share count- Fiscal year 2016: Diluted share count 1.6B
- Fiscal year 2017: Diluted share count 1.6B
- Fiscal year 2018: Diluted share count 1.5B
- Fiscal year 2019: Diluted share count 1.5B
- Fiscal year 2020: Diluted share count 1.7B
- Fiscal year 2021: Diluted share count 1.8B
- Fiscal year 2022: Diluted share count 1.8B
- Fiscal year 2023: Diluted share count 1.8B
- Fiscal year 2024: Diluted share count 1.8B
- Fiscal year 2025: Diluted share count 1.8B
From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Dividends and share repurchases
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
- Dividend per share
- 6.65 USD · Fiscal year 2025
- Dividend growth per year
- 3 y +5.2%5 y +6.6%10 y –
- Years without a cut
- at least 10 as far as the data goes
- Payout ratio
- of earnings 282% of free cash flow –
- Share count over 5 years
- +6.0% more shares – dilution
Dividend per share
The dividend per share rose in 5 years from 4.84 USD to 6.65 USD.
Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.- Fiscal year 2016: Dividend per share 2.35 USD
- Fiscal year 2017: Dividend per share 2.63 USD
- Fiscal year 2018: Dividend per share 3.95 USD
- Fiscal year 2019: Dividend per share 4.39 USD
- Fiscal year 2020: Dividend per share 4.84 USD
- Fiscal year 2021: Dividend per share 5.31 USD
- Fiscal year 2022: Dividend per share 5.71 USD
- Fiscal year 2023: Dividend per share 5.99 USD
- Fiscal year 2024: Dividend per share 6.29 USD
- Fiscal year 2025: Dividend per share 6.65 USD
Payout ratios
The payout ratio rose in 5 years from 177.9% to 281.8%.
Payout ratio (earnings)- Fiscal year 2016: Payout ratio (earnings) 64.7%
- Fiscal year 2017: Payout ratio (earnings) 79.7%
- Fiscal year 2018: Payout ratio (earnings) 107.9%
- Fiscal year 2019: Payout ratio (earnings) 83.1%
- Fiscal year 2020: Payout ratio (earnings) 177.9%
- Fiscal year 2021: Payout ratio (earnings) 82.3%
- Fiscal year 2022: Payout ratio (earnings) 86.1%
- Fiscal year 2023: Payout ratio (earnings) 220.2%
- Fiscal year 2024: Payout ratio (earnings) 263.2%
- Fiscal year 2025: Payout ratio (earnings) 281.8%
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Valuation over time
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users. Log in
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth+6.0% per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 6.0% per year on average, but more slowly than the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth−1.7% per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: −2.8% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it fell by 1.7% per year on average. The median company in the sector reached +7.5% per year.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net margin
Profit marginThe share of revenue that is left as profit after all costs.Example: Profit €60m on €500m revenue → margin 12%.More in the Academy: Lesson revenue, profit and margin6.9% last fiscal year
Sector Health Care: median 12.9% (63 symbols)
What does this mean? Of every 100 USD in revenue, 6.91 USD remained as profit – less than the median company in the sector (12.9%). Five years ago the margin was 10.1%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth– latest balance sheet
Sector Health Care: median 0.66 (40 symbols)
What does this mean? Equity is negative (e.g. due to share buybacks). A debt-to-equity ratio cannot be formed meaningfully then.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth282% Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The payout was higher than the earnings per share; it is paid from cash flow, from reserves or with new debt. Median company in the sector: 28%.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin10 of 10 fiscal years with a profit
What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
All figures as a table
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 31, 2025 | 61.2B | 4.2B | 6.9% | 2.36 | 6.65 | 282% |
| 2024 | Dec 31, 2024 | 56.3B | 4.3B | 7.6% | 2.39 | 6.29 | 263% |
| 2023 | Dec 31, 2023 | 54.3B | 4.9B | 9.0% | 2.72 | 5.99 | 220% |
| 2022 | Dec 31, 2022 | 58.1B | 11.8B | 20.4% | 6.63 | 5.71 | 86% |
| 2021 | Dec 31, 2021 | 56.2B | 11.5B | 20.5% | 6.45 | 5.31 | 82% |
| 2020 | Dec 31, 2020 | 45.8B | 4.6B | 10.1% | 2.72 | 4.84 | 178% |
| 2019 | Dec 31, 2019 | 33.3B | 7.9B | 23.7% | 5.28 | 4.39 | 83% |
| 2018 | Dec 31, 2018 | 32.8B | 5.7B | 17.4% | 3.66 | 3.95 | 108% |
| 2017 | Dec 31, 2017 | 28.2B | 5.3B | 18.8% | 3.30 | 2.63 | 80% |
| 2016 | Dec 31, 2016 | 25.6B | 6.0B | 23.2% | 3.63 | 2.35 | 65% |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q2/26 | Jun 30, 2026 | 17.0B | 3.6B | 21.3% | 2.03 | 1.73 | 85% |
| Q1/26 | Mar 31, 2026 | 15.0B | 695.0M | 4.6% | 0.39 | 1.73 | 444% |
| Q4/25 | Dec 31, 2025 | 16.6B | 1.8B | 10.9% | 1.02 | 1.73 | 170% |
| Q3/25 | Sep 30, 2025 | 15.8B | 186.0M | 1.2% | 0.10 | 1.64 | 1,640% |
| Q2/25 | Jun 30, 2025 | 15.4B | 938.0M | 6.1% | 0.52 | 1.64 | 315% |
| Q1/25 | Mar 31, 2025 | 13.3B | 1.3B | 9.6% | 0.72 | 1.64 | 228% |
| Q4/24 | Dec 31, 2024 | 15.1B | −22.0M | −0.1% | −0.02 | 1.64 | – |
| Q3/24 | Sep 30, 2024 | 14.5B | 1.6B | 10.8% | 0.88 | 1.55 | 176% |
| Q2/24 | Jun 30, 2024 | 14.5B | 1.4B | 9.5% | 0.77 | 1.55 | 201% |
| Q1/24 | Mar 31, 2024 | 12.3B | 1.4B | 11.1% | 0.77 | 1.55 | 201% |
| Q4/23 | Dec 31, 2023 | 14.3B | 822.0M | 5.7% | 0.46 | 1.55 | 337% |
| Q3/23 | Sep 30, 2023 | 13.9B | 1.8B | 12.8% | 1.00 | 1.48 | 148% |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary| Period | Purchases | Sales | Net |
|---|---|---|---|
| 3 months | $00 people | $8.2M1 person | −$8.2M |
| 6 months | $00 people | $8.2M1 person | −$8.2M |
| 12 months | $00 people | $18.9M3 people | −$18.9M |
Latest transactions
- Aug 14, 2026 Donoghoe Nicholas Officer Open-market sale 32,710 shares · $8.2M · SEC
- Mar 4, 2026 Purdue David Ryan Officer Open-market sale 5,230 shares · $1.2M · SEC
- Mar 2, 2026 Siatis Perry C Officer Open-market sale · 10b5-1 plan 2,600 shares · $611.7K · SEC
- Mar 2, 2026 Siatis Perry C Officer Open-market sale · 10b5-1 plan 10,291 shares · $2.4M · SEC
- Mar 2, 2026 Siatis Perry C Officer Open-market sale · 10b5-1 plan 5,777 shares · $1.3M · SEC
- Feb 25, 2026 Siatis Perry C Officer Open-market sale · 10b5-1 plan 22,381 shares · $5.1M · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Trend score +80
Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+0
Relative strength+15
Volatility and trend strength
ADX 14 (trend strength)34.3
Rel. strength 60 d+11.5%
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
More stocks from Health Care
News
Latest news
AbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story? Yahoo Finance · Oct 21, 17:18
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue? Yahoo Finance · Oct 21, 15:20
Forget Social Security: 5 High-Yield Stocks Retirees Are Buying Instead Yahoo Finance · Oct 21, 14:05
Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence Yahoo Finance · Oct 21, 14:00
AbbVie races into F1 as pharma companies continue push into sport Yahoo Finance · Oct 21, 13:40
AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian Cancer Yahoo Finance · Oct 21, 13:01
What Happens To Merck Stock If Keytruda Sales Stop Growing? Yahoo Finance · Oct 21, 04:20
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? Yahoo Finance · Oct 20, 23:35
Posts
No posts on ABBV yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules